| Literature DB >> 31440126 |
Linus Haberbosch1,2, Abhishek Datta3, Chris Thomas3, Andreas Jooß1, Arvid Köhn1, Maria Rönnefarth1,4, Michael Scholz5, Stephan A Brandt1, Sein Schmidt1,4.
Abstract
BACKGROUND: While alternating current stimulation (ACS) is gaining relevance as a tool in research and approaching clinical applications, its mechanisms of action remain unclear. A review by Schutter and colleagues argues for a retinal origin of transcranial ACS' neuromodulatory effects. Interestingly, there is an alternative application form of ACS specifically targeting α-oscillations in the visual cortex via periorbital electrodes (retinofugal alternating current stimulation, rACS). To further compare these two methods and investigate retinal effects of ACS, we first aim to establish the safety and tolerability of rACS.Entities:
Keywords: adverse events; electrical stimulation; feasibility; finite element modeling; retinofugal alternating current stimulation; safety; tolerability
Year: 2019 PMID: 31440126 PMCID: PMC6692662 DOI: 10.3389/fnins.2019.00783
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
FIGURE 1Model segmentation and finite element analysis. The ultra-high resolution MIDA model was adapted for analysis in this study. (A) Skin tissue mask with periorbital electrodes (gray: electrode; blue: sponge). (B) The modeled brain, cranial nerves, blood vessels, eye structure, optic nerves, and electrodes (both active periorbital and the return inion electrode shown). (C) Zoomed view corresponding to the dashed section in panel (B) highlighting segmentation detail in the region of interest. Finite element analysis of current flow produced by rACS: Induced electric field magnitude plots on the cortical and eye level perspective (D) and bottom view (E). A representative axial 2D cross-section view of electric field magnitude following the retinofugal tract was chosen and plotted (F). Panel (G) shows the induced electric field on the eyes and optic nerve. Panel (H) shows the rear view. Panel (I) shows the primary visual cortex (V1) corresponding to the dashed section in panel (H). A representative 2D axial cross-section view of electric field magnitude taken at the level of half of the visual cortex along the superior–inferior plane is shown in panel (J).
Assigned electrical conductivities.
| Scalp | 0.465 |
| Muscle | 0.35 |
| Skull | 0.01 |
| CSF | 1.65 |
| Gray Matter | 0.276 |
| White Matter | 0.126 |
| Fat | 0.04 |
| Blood vessels | 0.7 |
| Eye Lens | 0.32 |
| Eye Retina/Choroid/Sclera | 0.623 |
| Eye Vitreous | 1.55 |
| Eye Cornea | 0.5 |
| Eye Aqueous | 1.5 |
| Optic Tract/Optic Chiasm/Cranial Nerve II | 0.126 |
| Air | 1.00E−07 |
| Sponge (felt buffer) | 1.84 |
| Periorbital electrode (gold electrodes) | 4.10E+07 |
| Inion electrode (stainless steel) | 1.45E+06 |
Comparison of stimulation parameters.
| Safety limits ( | – | – | – | – | 25 | – | – | 0.000400 |
| Safety limits ( | 0.5 | 0.035 | 10 | – | 14.29 | 85.714 | – | – |
| (52.400) | ||||||||
| rACS | 0.35 | 0.35 | 10 | 10 | 1 | 0.599 | 0.000035 | 0.0001 |
| rACS (effective amplitude) | 0.25 | 0.35 | 10 | 10 | 0.71 | 0.423 | 0.000025 | 0.000071 |
| Electrosleep ( | 25 | 1.25 | 60 | 100 | 20 | 72 | 0.00025 | 0.0002 |
| TCES ( | 1.2 | 1 | 5 | 20 | 1.2 | 0.36 | 0.00006 | 0.00006 |
| TCES ( | 0.28 | 1.25 | 7 | 10 | 0.22 | 0.094 | 0.000028 | 0.000022 |
| TCES ( | 3 | 0.35 | 7 | – | 8.57 | – | – | – |
| TCES ( | 0.08 | 0.35 | 7 | – | 0.22 | – | – | – |
| tACS ( | 0.4 | 16 | 5 | 10 | 0.03 | 0.008 | 0.00004 | 0.000003 |
| tSDCS ( | 0.25 | 16 | 4 | 10 | 0.02 | 0.004 | 0.000025 | 0.000002 |
| tDCS ( | 1 | 35 | 9 | – | 0.03 | – | – | – |
Modeling data and comparison to safety limits.
| Safety limits | 14.29 | 42 | |
| rACS (retina) | Max | 0.124 | 1.99 |
| Mean | 0.007 | 0.11 | |
| Median | 0.005 | 0.08 | |
| rACS (optic nerve) | Max | 0.033 | 2.6 |
| Mean | 0.003 | 0.2 | |
| Median | 0.002 | 0.14 | |
| rACS (cortex) | Max | 0.013 | 0.47 |
| Mean | 0.001 | 0.05 | |
| Median | 0.001 | 0.04 | |
| rACS (V1) | Max | 0.003 | 0.12 |
| Mean | 0.001 | 0.03 | |
| Median | 0.001 | 0.03 |
Adverse events for rACS and PS.
| Pain (overall) | During | 8 | 40 | 4 | 20 |
| After | 0 | 0 | 2 | 10 | |
| Fatigue | During | 7 | 35 | 4 | 20 |
| After | 7 | 35 | 4 | 20 | |
| Tingling | During | 14 | 70 | 0 | 0 |
| After | 0 | 0 | 0 | 0 | |
| Headache | During | 0 | 0 | 3 | 15 |
| After | 1 | 5 | 1 | 5 | |
| Itching | During | 6 | 30 | 0 | 0 |
| After | 5 | 25 | 0 | 0 | |
| Burning | During | 6 | 30 | 0 | 0 |
| After | 0 | 0 | 0 | 0 | |
| Difficulties in Concentrating | During | 0 | 0 | 0 | 0 |
| After | 0 | 0 | 2 | 10 | |
| Metallic Taste | During | 3 | 15 | 0 | 0 |
| After | 0 | 0 | 0 | 0 | |
| Muscle twitches | During | 3 | 15 | 0 | 0 |
| After | 0 | 0 | 0 | 0 | |
| Acute mood changes | During | 0 | 0 | 0 | 0 |
| After | 0 | 0 | 0 | 0 | |
| Nausea | During | 0 | 0 | 0 | 0 |
| After | 0 | 0 | 0 | 0 | |
FIGURE 2Adverse events. A comparison of adverse events between rACS (green) and PS (blue). None of the depicted differences were significant in Bonferroni-corrected multiple comparisons. (A) Depicted is the mean rating (NRS-11) of overall pain and discomfort in affected subjects during and after stimulation. Error bars represent the standard deviation. (B) Comparison of shared adverse events (fatigue and headache) in percentage of subjects.
Results of the Wilcoxon-signed ranks tests.
| Stimtype (rACS vs. PS) | Pain (overall) | During | –0.987a | 0.323 |
| After | –1.342b | 0.180 | ||
Results of the Fisher’s exact tests.
| Stimtype (rACS vs. PS) | Fatigue | During | 0.480 |
| After | 0.480 | ||
| Difficulties in Concentrating | During | – | |
| After | 0.487 | ||
| Headache | During | 0.231 | |
| After | 1.000 | ||
| Itching | During | 0.020∗ | |
| After | 0.047∗ | ||
| Burning | During | 0.020∗ | |
| After | – | ||
| Tingling | During | 0.000∗ | |
| After | – | ||